Home > Publications database > Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway. > print

001     303966
005     20250823114644.0
024 7 _ |a 10.1038/s41416-025-03038-w
|2 doi
024 7 _ |a pmid:40835748
|2 pmid
024 7 _ |a 0007-0920
|2 ISSN
024 7 _ |a 1532-1827
|2 ISSN
037 _ _ |a DKFZ-2025-01735
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Støer, Nathalie C
|0 0000-0001-8994-9332
|b 0
245 _ _ |a Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
260 _ _ |a Edinburgh
|c 2025
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1755860803_12319
|2 PUB:(DE-HGF)
|x Erratum/Correction
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. / epub
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Vangen, Siri
|0 0000-0003-4681-4774
|b 1
700 1 _ |a Singh, Deependra
|b 2
700 1 _ |a Turzanski-Fortner, Renée
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 3
|u dkfz
700 1 _ |a Hofvind, Solveig
|0 0000-0003-0178-8939
|b 4
700 1 _ |a Ursin, Giske
|b 5
700 1 _ |a Botteri, Edoardo
|b 6
773 _ _ |a 10.1038/s41416-025-03038-w
|0 PERI:(DE-600)2002452-6
|p nn
|t British journal of cancer
|v nn
|y 2025
|x 0007-0920
909 C O |o oai:inrepo02.dkfz.de:303966
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-19
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRIT J CANCER : 2022
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-19
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-19
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BRIT J CANCER : 2022
|d 2024-12-19
920 1 _ |0 I:(DE-He78)C180-20160331
|k C180
|l Krebsepidemiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C180-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21